FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097335047> ?p ?o ?g. }

• W3097335047 endingPage "38" @default.
• W3097335047 startingPage "37" @default.
• W3097335047 abstract "Evidence-based medicine is predicated on the concept of making clinical decisions based on the best available clinical evidence. One of the great concerns for dermatologists at the onset of the pandemic was to determine how to treat patients with psoriasis, atopic dermatitis, autoimmune bullous disorders, and connective tissue diseases who were prescribed immunosuppressants or immunomodulators.1Drenovska K. Schmidt E. Vassileva S. Covid-19 pandemic and the skin.Int J Dermatol. 2020; https://doi.org/10.1111/ijd.15189Crossref PubMed Scopus (23) Google Scholar In the topsy-turvy COVID-19 universe, guidelines needed to be developed posthaste, based on expert opinion rather than data. Gadarowski et al2Gadarowski M.B. Balogh E.A. Bashyam A.M. Feldman S.R. Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.J Dermatolog Treat. 2020; https://doi.org/10.1080/09546634.2020.1808154Crossref PubMed Scopus (4) Google Scholar(p1) note that “in March 2020, it was unclear whether dermatology patients on biologics or other forms of systemic therapy should continue medication, or whether it would be inappropriate to initiate such treatment in an at-risk cohort.” The essence of the American Academy of Dermatology guidelines (https://www.aad.org/member/practice/coronavirus/clinical-guidance/biologics) is that patients on these agents should not discontinue them unless testing positive for COVID-19; they may be readministered after COVID-19 resolution. Initiation of such therapy is based on disease severity and comorbidities, with postponement of administration for high-risk patients (>60 years old; diabetes, cardiovascular, hepatic, renal, or respiratory disease). Guidelines from multiple international organizations all concurred that patients should not discontinue treatment without first speaking with their providers.2Gadarowski M.B. Balogh E.A. Bashyam A.M. Feldman S.R. Examining recommendations for the use of biologics and other systemic therapies during COVID-19: a review and comparison of available dermatology guidelines and patient registries.J Dermatolog Treat. 2020; https://doi.org/10.1080/09546634.2020.1808154Crossref PubMed Scopus (4) Google Scholar Entering year 2 of the pandemic, data are beginning to accrue that will help confirm or deny the validity of these guidelines. Haberman et al3Haberman R. Axelrad J. Chen A. et al.Covid-19 in immune-mediated inflammatory diseases—case series from New York.N Engl J Med. 2020; 383: 85-88Crossref PubMed Scopus (338) Google Scholar performed a prospective study on 86 patients with immune-mediated inflammatory diseases on biologics and immunomodulatory therapies who were confirmed to have COVID-19 (59 patients) or highly suspected to have the infection (27 patients). Only 14 of the 86 patients required hospitalization, which was similar to the general population. The authors concluded that the baseline use of biologics was not associated with worsened outcomes while acknowledging that their study was small.3Haberman R. Axelrad J. Chen A. et al.Covid-19 in immune-mediated inflammatory diseases—case series from New York.N Engl J Med. 2020; 383: 85-88Crossref PubMed Scopus (338) Google Scholar Gisondi et al4Gisondi P. Facheris P. Dapavo P. et al.The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.Br J Dermatol. 2020; 183: 373-374Crossref PubMed Scopus (91) Google Scholar performed a retrospective study of 5206 patients with psoriasis on biologics (tumor necrosis factor [TNF], interleukin (IL) 17, IL-12/23, and IL-23 inhibitors) during the Italian pandemic. Only 4 patients, all with COVID-19 risk factors, required hospitalization for pneumonia; none died. Despite the limitations of this study, the results were reassuring for the continued use of biologic agents during the pandemic.4Gisondi P. Facheris P. Dapavo P. et al.The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.Br J Dermatol. 2020; 183: 373-374Crossref PubMed Scopus (91) Google Scholar In this issue of the Journal of the American Academy of Dermatology, Yousaf et al5Yousaf A. Gayam S. Feldman S. Zinn Z. Kolodney M. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors and/or methotrexate: a multi-center research network study.J Am Acad Dermatol. 2021; https://doi.org/10.1016/j.jaad.2020.09.009Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar evaluated whether patients on TNF inhibitors and/or methotrexate are at increased risk of COVID-19–related outcomes. A total of 214 patients with COVID-19 were identified with recent TNF inhibitor or methotrexate exposure and compared to 31,862 patients with COVID-19 without TNF inhibitor or methotrexate exposure. After propensity matching, the likelihoods of hospitalization and mortality were not significantly different between the treatment and nontreatment groups, allowing the investigators to conclude that patients with recent TNF inhibitor and/or methotrexate exposure do not have increased hospitalization or mortality compared to patients with COVID-19 without recent TNF inhibitor and/or methotrexate exposure. I applaud every dermatologist involved with the rapid development of the thoughtful American Academy of Dermatology guidelines for COVID-19 that allowed us to navigate unchartered seas. The coming year(s) will bring us multiple studies that may modify these guidelines accordingly. It is imperative that we all keep abreast of these developments in real time." @default.
• W3097335047 created "2020-11-09" @default.
• W3097335047 creator A5071340921 @default.
• W3097335047 date "2021-01-01" @default.
• W3097335047 modified "2023-10-17" @default.
• W3097335047 title "Evidence following guidelines: Another COVID-19 paradox" @default.
• W3097335047 cites W3018029174 @default.
• W3097335047 cites W3020611303 @default.
• W3097335047 cites W3048044127 @default.
• W3097335047 cites W3084628013 @default.
• W3097335047 cites W3087200990 @default.
• W3097335047 doi "https://doi.org/10.1016/j.jaad.2020.10.070" @default.
• W3097335047 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7598361" @default.
• W3097335047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33130184" @default.
• W3097335047 hasPublicationYear "2021" @default.
• W3097335047 type Work @default.
• W3097335047 sameAs 3097335047 @default.
• W3097335047 citedByCount "3" @default.
• W3097335047 countsByYear W30973350472021 @default.
• W3097335047 countsByYear W30973350472022 @default.
• W3097335047 crossrefType "journal-article" @default.
• W3097335047 hasAuthorship W3097335047A5071340921 @default.
• W3097335047 hasBestOaLocation W30973350471 @default.
• W3097335047 hasConcept C126322002 @default.
• W3097335047 hasConcept C16005928 @default.
• W3097335047 hasConcept C17744445 @default.
• W3097335047 hasConcept C177713679 @default.
• W3097335047 hasConcept C199539241 @default.
• W3097335047 hasConcept C2778329239 @default.
• W3097335047 hasConcept C2779134260 @default.
• W3097335047 hasConcept C2779473830 @default.
• W3097335047 hasConcept C3008058167 @default.
• W3097335047 hasConcept C512399662 @default.
• W3097335047 hasConcept C524204448 @default.
• W3097335047 hasConcept C71924100 @default.
• W3097335047 hasConcept C83867959 @default.
• W3097335047 hasConcept C89623803 @default.
• W3097335047 hasConceptScore W3097335047C126322002 @default.
• W3097335047 hasConceptScore W3097335047C16005928 @default.
• W3097335047 hasConceptScore W3097335047C17744445 @default.
• W3097335047 hasConceptScore W3097335047C177713679 @default.
• W3097335047 hasConceptScore W3097335047C199539241 @default.
• W3097335047 hasConceptScore W3097335047C2778329239 @default.
• W3097335047 hasConceptScore W3097335047C2779134260 @default.
• W3097335047 hasConceptScore W3097335047C2779473830 @default.
• W3097335047 hasConceptScore W3097335047C3008058167 @default.
• W3097335047 hasConceptScore W3097335047C512399662 @default.
• W3097335047 hasConceptScore W3097335047C524204448 @default.
• W3097335047 hasConceptScore W3097335047C71924100 @default.
• W3097335047 hasConceptScore W3097335047C83867959 @default.
• W3097335047 hasConceptScore W3097335047C89623803 @default.
• W3097335047 hasIssue "1" @default.
• W3097335047 hasLocation W30973350471 @default.
• W3097335047 hasLocation W30973350472 @default.
• W3097335047 hasLocation W30973350473 @default.
• W3097335047 hasOpenAccess W3097335047 @default.
• W3097335047 hasPrimaryLocation W30973350471 @default.
• W3097335047 hasRelatedWork W3032320397 @default.
• W3097335047 hasRelatedWork W3103289217 @default.
• W3097335047 hasRelatedWork W3106370311 @default.
• W3097335047 hasRelatedWork W3108360120 @default.
• W3097335047 hasRelatedWork W3119540162 @default.
• W3097335047 hasRelatedWork W3152916563 @default.
• W3097335047 hasRelatedWork W4313474620 @default.
• W3097335047 hasRelatedWork W4327956415 @default.
• W3097335047 hasRelatedWork W4381432928 @default.
• W3097335047 hasRelatedWork W4381942459 @default.
• W3097335047 hasVolume "84" @default.
• W3097335047 isParatext "false" @default.
• W3097335047 isRetracted "false" @default.
• W3097335047 magId "3097335047" @default.
• W3097335047 workType "article" @default.